secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001683168-26-003446
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Valion Bio appoints Melinda Lackey as General Counsel and SVP of Legal Affairs
------------------------------------------------------------------------------

- Melinda Lackey, age 49, appointed as GC and SVP of Legal Affairs, effective May 4, 2026.
- Prior role: SVP Legal & Administration at Alaunos Therapeutics (TCRT); also served at Kuur Therapeutics and Winston & Strawn.
- Employment agreement: base salary $321,000/year, eligible for annual bonus up to 35% of base, and option grant of 45,000 shares.
- Lackey will oversee legal functions for Valion's Entolimod ARS program and CDMO subsidiary Velocity Bioworks.
- Company (Nasdaq: VBIO) is a clinical-stage immunotherapeutics firm advancing Entolimod via FDA Animal Rule pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826003446/0001683168-26-003446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826003446/valion_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-003446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer